Biotech Values

[dewophile]

i think the price dynamics typically seen when generics are introduced may not hold when there is a high barrier to entry and only 2 drugs are competing for market share. that is, i think SNY will fight for market share and pricing won't be static. it may boil down to COGs.neither are completely vertically integrated, but SNY initially may have an advantage based on scale. I think a more conservative assumption is 50% market share when steady state if you will is reached - likely at a price point close to the discount you assume. jmo
on the other hand, what approval as a sole generic implies for the FOB platform in general is HUGE. it's a complete validation of MNTA's characterization platform for sugars - they key piece (as I know you know) in validating sameness for glycoproteins